Manuel P. Pereira is an investigator for Sanofi and Trevi Therapeutics; is a consultant for Galderma; and has received speaker honoraria/travel fees from AbbVie, Beiersdorf, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, P.G. Unna Academy and Trevi Therapeutics.

Claudia Zeidler has received speaker honoraria/travel fees from AbbVie, Beiersdorf, Dermascence and Leo Pharma and is an investigator for Abbvie, Boehringer Ingelheim, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi, Regeneron and UCB.

Sonja Ständer is an investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics and Vanda Pharmaceuticals, and is a consultant and/or member of the advisory board for Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene, Clexio Biosciences, DS Biopharma, Galderma, Menlo Therapeutics, Novartis, Perrigo and Trevi Therapeutics.

Open Research

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1Pereira MP, Steinke S, Zeidler C et al. European academy of dermatology and venereology European prurigo project: Expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059–1065.
10.1111/jdv.14570
CAS PubMed Web of Science® Google Scholar
2Ständer S, Pereira MP, Berger T et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5: e42.
10.1097/itx.0000000000000042
Google Scholar
3Simpson EL, Forman S, Silverberg JI et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol 2021; 85: 62–70.
10.1016/j.jaad.2021.02.028
CAS PubMed Web of Science® Google Scholar
4He Y, Ji S, Yu Q. Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report. Dermatol Ther 2021; 34: e14878.
10.1111/dth.14878
PubMed Web of Science® Google Scholar
5Buttgereit T, Grekowitz EM, Metz M. Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab. JAAD Case Rep 2021; 15: 36–38.
10.1016/j.jdcr.2021.06.028
PubMed Google Scholar
6Gordon SC, Trudeau S, Regev A et al. Baricitinib and primary biliary cholangitis. J Transl Autoimmun 2021; 4: 100107.
10.1016/j.jtauto.2021.100107
CAS PubMed Google Scholar
7Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J Allergy Clin Immunol 2017; 140: 633–643.
10.1016/j.jaci.2017.07.006
PubMed Web of Science® Google Scholar
8Ständer S, Yosipovitch G, Legat FJ et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med 2020; 382: 706–716.
10.1056/NEJMoa1908316
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume36, Issue6

June 2022

Pages e486-e488

Improvement of chronic nodular prurigo with baricitinib

Conflicts of interest

Open Research

Data availability statement

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Improvement of chronic nodular prurigo with baricitinib

Conflicts of interest

Open Research

Data availability statement

References

Citing Literature

References

Related

Information